Navigation Links
PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
Date:2/3/2009

- Ataluren designated as generic name for PTC124 -

SOUTH PLAINFIELD, N.J., Feb. 3 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has successfully completed patient enrollment of its pivotal clinical trial of PTC124 in patients with nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Accrual was completed two months ahead of schedule. The company also announced today that PTC124 has been issued the generic name, ataluren.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

The one-year, multi-center, randomized, double-blind, placebo-controlled study is designed to determine whether ataluren can improve walking, muscle function and strength in patients with nmDMD/BMD. It will also evaluate ataluren's long-term safety profile over a longer term than in previous studies. The pivotal trial is ongoing at 37 sites on four continents and in 11 countries. The study has enrolled 174 patients across the United States, Europe, Canada, Australia, and Israel.

"This trial represents a critical milestone for the entire DMD/BMD community - 20 years after sequencing the dystrophin gene we have the first pivotal study for a potential disease-modifying therapy," said Brenda Wong, MD, associate professor of pediatrics and neurology, Cincinnati Children's Hospital Medical Center. "The rapid accrual is a testament to the commitment of boys with DMD/BMD and their families and the strong sense of urgency on the part of so many investigational teams around the world."

"Duchenne/Becker muscular dystrophy is a rare disorder and patients whose disease is due to a nonsense mutation represent only 13 percent of these cases, which created an enrollment challenge. However, the collaborative approach taken by clinical trial sites, advocacy groups, and PTC Therapeutics
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
2. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
3. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
4. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
7. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
8. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
9. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Introduction of new ... tools for radiosurgery/SBRT   The "Elements" ... enhancing the workflow for difficult to treat indications ... - comes full circle with the introduction of ... Elements enable on-the-fly generation of consistent treatment plans ...
(Date:4/24/2015)... Hi-Tech Pharmaceuticals refutes the results from ... of reliable scientific principles and methods and therefore ... of adulteration. The FDA is resting its very, ... misguided hope, that Methylphenylethylamine is not found in ... multiple other studies and cannot be relied on ...
(Date:4/24/2015)... , April 24, 2015 Hospira, ... in the development of biosimilar therapies, spoke about the ... at the European Generics Association (EGA) annual European Biosimilars ... The company also announced the publication of a ... to achieving the full promise of biosimilars." ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7
(Date:4/25/2015)... 2015 The URO CENTER of NEW YORK ... chosen by the New York Academy of Medicine to receive ... the field of Urology. , Dr. Ferdinand Valentine, born in ... diseases. He was a man of rare and attractive ... Not only did he devote his life to his ...
(Date:4/24/2015)... Constellations Recovery celebrates the opening of ... Just 35 miles from New York City, Constellations Recovery ... life while recovering from addiction. The Open House, which ... therapists, doctors and treatment centers to see the residence, ... opportunities offered by Constellations Recovery.,  , The newly opened ...
(Date:4/24/2015)... April 24, 2015 The Fastest Fat Loss ... their great success of the Xtreme Fat Loss Diet, has ... The fat loss blueprint that claims to help one lose ... of HealthyandFitZone.com's Stan Stevenson, prompting an investigative review. , "Our ... the creators spent years researching and experimenting with these methods ...
(Date:4/24/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining how ... citizens . , Senior citizens may be considered ... they cannot find affordable coverage. By comparing online auto ... coverage for their cars at the best prices. ... provides free leads from various agencies that are in ...
(Date:4/24/2015)... “Kind,” “selfless,” “the voice of reason” and ... Weiner described pediatric oncology nurse Laura Vasquez of Children’s ... during her five-year battle with a malignant brain tumor. ... and numerous experimental treatments, Vasquez continued caring for Alexa, ... was not in the hospital and even sitting vigil ...
Breaking Medicine News(10 mins):Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Low Cost Auto Insurance Quotes for Senior Citizens 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4
... New web-based research has quantified the attractiveness of the ... features of one woman into 243 variations with differing ... widths. Then more than 34,000 people judged the attractiveness ... the same in all of the photos, researchers found ...
... Old Republic International Corporation (NYSE: ORI ... the payment of the regular quarterly cash dividend of 17 ... March 13, 2009 to shareholders of record on March 4, ... rate initially approved for the second quarter of 2008. ...
... as Asian AffiliateNEW YORK and SINGAPORE, Feb. 26 ... prevention services, has signed an affiliation agreement with ... group based in Singapore and a subsidiary of ... medicine programs throughout Asia. Under the agreement, ParkwayHealth ...
... 274 adults with intellectual disabilities currently receiving funding ... , Washington, DC(February 23, 2009)The Supports Intensity ... for people with intellectual disability based on individual ... tool, unlike adaptive behavior instruments or other measures ...
... at the UCSF-Gladstone Institute for Virology and Immunology Center ... development of the next generation of HIV/AIDS researchers and ... published in the American Journal for Public Health ... of the AJPH website, the program focuses on overcoming ...
... Abbott ( NYSE: ABT ),today announced that it has ... now a wholly owned subsidiary of Abbott and has been,renamed ... acquisition of AMO enhances and strengthens Abbott,s diverse mix of,medical ... large and,growing eye care market. Abbott Medical Optics holds ...
Cached Medicine News:Health News:Plastic and reconstructive surgery ... in brief 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 3Health News:Supports Intensity Scale is effective for identifying needs in people with intellectual disability 2Health News:Effective mentoring critical to HIV/AIDS research efforts 2Health News:Abbott Completes Acquisition of Advanced Medical Optics 2